GlassScriptPhysician profile
Asad E Chaudhry
NPI 1538339213
$1,735.18
in general payments reported to CMS, 2019-2025
23 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $78.37 · 2021: $32.88 · 2022: $199 · 2023: $419 · 2024: $253 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.74 |
| Education | $214.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.36 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $214.33 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Pfizer INC. | $173.01 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $142.24 | 2019-2024 | Xarelto |
| Amgen INC. | $136.14 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $112.17 | 2019-2023 | |
| Scpharmaceuticals INC. | $101.92 | 2025 | |
| Merck Sharp & Dohme LLC | $85.00 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $61.50 | 2022-2025 | Camzyos |
| Baxter Healthcare | $52.85 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $48.85 | 2019 | |
| Esperion Therapeutics, INC. | $39.16 | 2022-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $37.27 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.94 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.87 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $24.32 | 2023 | Vitalpatch Rtm |
| Amarin Pharma, INC. | $22.38 | 2019 | |
| Astellas Pharma US INC | $21.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2023 | Jardiance |
| Boston Scientific Corporation | $13.26 | 2019 | |
| Tactile Systems Technology INC | $12.39 | 2019 | |
| Atricure, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.